Akums Drugs & Pharma to Invest $24 Million in Zambian Healthcare Subsidiary

Akums Drugs & Pharma has announced a $24 million investment in its newly formed subsidiary, Akums Healthcare (Zambia) Private Limited, over the next three years. The subsidiary, incorporated on October 13, 2025, will focus on establishing a local pharmaceutical manufacturing facility to strengthen Akums’ footprint in Africa. The company currently holds a 51% stake in the Zambian entity.

Strengthening Local Production and Regional Access

The investment aims to support Zambia’s expanding healthcare needs, where nearly 85% of essential medicines are imported. With the Zambian pharmaceutical market valued at $200 million and projected to exceed $300 million by 2030, Akums’ expansion will enhance local manufacturing capacity, improve medicine availability, and bolster supply resilience for Zambia and surrounding SADC nations.

Strategic Expansion into Africa’s Growing Pharma Market

This move positions Akums to leverage Africa’s rising demand for quality pharmaceuticals while strengthening its international presence. Establishing on-ground production will reduce dependence on imports, accelerate regional distribution, and open new growth opportunities across Southern Africa’s fast-developing healthcare ecosystem.